Compare Crispr Therapeutics AG (CRSP) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Xpeng Inc - ADR — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while Xpeng Inc - ADR trades at $11.77 (market cap $11.15B). The key difference: Xpeng Inc - ADR is far larger — about 2.1× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| CRSP | XPEV | |
|---|---|---|
Market Cap | $5.23B | $11.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $28.07 |
52-Week Low | $44.34 | $11.68 |
Enterprise Value | $3.65B | $13.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
XPeng (XPEV) trades at $11.74, down 2.17% today, with a bearish technical signal but oversold RSI. Revenue surged to $76.72B in 2025, yet net losses persist at -$1.14B. Recent news highlights July 2026 deliveries of 38,027 vehicles, up 4% YoY, and expansion into robotics and autonomous driving.
Outlook: Analyst consensus is bullish with a $17.00 price target, but risks include intense EV competition and ongoing profitability challenges. Upside hinges on new model success and global expansion, while cash flow volatility and high debt remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
